Drug Trial Radar · NCT05946876
A Phase 1 Study of XH-S003 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Aug 24, 2023
Primary completion
Jul 11, 2024
Study completion Aug 14, 2024
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, randomised, first-in-human, double-blinded, placebo-controlled, SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose) study to assess the PK, safety, and tolerability of XH-S003 in healthy volunteers. In addition, this study evaluates the effects of food on XH-S003 under a two-period, cross-over study setting.
Conditions
- Healthy
Interventions
XH-S003 (A)Drug
IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Placebo (B)Other
Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Part A: Upto 10 days
- Number of participants with adverse events (AEs)Time frame: Part B: Up to 28 days
- Number of participants with adverse events (AEs)Time frame: Part C: Up to 7 days
- Number of participants with clinical laboratory abnormalitiesTime frame: Part A: Upto 10 days
- Number of participants with clinical laboratory abnormalitiesTime frame: Part B: Up to 28 days
- Number of participants with clinical laboratory abnormalitiesTime frame: Part C: Up to 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.